Patents Assigned to Chong Kun Dang Pharmaceutical Corp.
-
Patent number: 10287255Abstract: A compound of formula (I), having histone deacetylase 6 (HDAC6) inhibitory activity, wherein X, Q, N, R1, R2, L, and n are as described, isomers thereof, or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions comprising the same, a method of treating disease using the composition, and methods for preparing the novel compounds. The novel compounds according to the present invention have histone deacetylase 6 (HDAC6) inhibitory activity, and are effective for the prevention or treatment of HDAC6-associated diseases, including cancer, inflammatory diseases, autoimmune diseases, neurological diseases and neurodegenerative disorders.Type: GrantFiled: March 12, 2015Date of Patent: May 14, 2019Assignee: CHONG KUN DANG PHARMACEUTICAL CORP.Inventors: Hyeseung Song, Changgon Lee, Dalyong Kwak, Jaeyoung Lee, Suyeal Bae, Yuntae Kim, Daekwon Bae, Nina Ha, Miseon Bae, Jihyun Kim
-
Publication number: 20190024115Abstract: The present invention relates to a transgenic pig in which an immune rejection response is suppressed during xenotransplantation, wherein a gene coding for heme oxygenase-1 (HO-1) and a gene coding for tumor necrosis factor receptor 1-Fc (TNFR1-Fc) are simultaneously expressed and a gene coding for ?-1,3-galactosyltransferase (GGTA1) is knocked out; and a method for producing the same. The transgenic pig of the present invention, in which the genes coding for human HO-1 and TNFR1-Fc fusion protein are simultaneously expressed and the gene coding for GGTA1 is knocked out, may reduce oxidative stress during organ isolation and in vitro culture by antioxidative reaction, cytoprotective function, etc., and may also reduce a TNF-?-mediated inflammatory response in early transplantation by TNFR1-Fc expression.Type: ApplicationFiled: November 11, 2016Publication date: January 24, 2019Applicants: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, CHONG KUN DANG PHARMACEUTICAL CORP.Inventors: Byeong Chun Lee, Cu Rie Ahn, Geon A Kim, Su Cheong Yeom, Su Jin Kim, Bum Rae Cho, Eun Mi Lee, Sang Hoon Lee, In Chang Hwang, Hye Jin Hong
-
Patent number: 9994627Abstract: The present invention relates to a method for purifying an erythropoietin analog having a low isoelectric point below 4 by adding an N-linked sugar chain with high purity. In accordance with the present invention, the erythropoietin analog having an isoelectric point below 4, which is an isoform having more sialic acid residues, can be effectively purified via three-step chromatographic processes in short time at lower cost.Type: GrantFiled: September 28, 2012Date of Patent: June 12, 2018Assignee: CHONG KUN DANG PHARMACEUTICAL CORP.Inventors: Yeo-Wook Koh, Sang-Yong Lee, Cook-Hee Kim, Seung-Hui Lee, Ha-Na Kim, Su-Yon Kim, Jin-Hyun Seong, Yong-Hyun Cho
-
Patent number: 9980953Abstract: The present invention relates to a pharmaceutical combined composition for preventing or treating cancer comprising a compound of formula 1 or a pharmaceutically acceptable salt thereof and topoisomerase inhibitor as active ingredients. The pharmaceutical combined composition of the present invention specifically inhibits cell proliferation and induces apoptosis as to various cancers such as colorectal cancer and ovarian cancer that a vascular disrupting agent cannot treat due to a complex inhibition mechanism of neoplasm of the compound of formula 1 and the pharmaceutically acceptable salt thereof and topoisomerase inhibitor, and thereby it can be usefully used for preventing and treating cancer.Type: GrantFiled: March 2, 2017Date of Patent: May 29, 2018Assignees: CHONG KUN DANG PHARMACEUTICAL CORP., NATIONAL CANCER CENTERInventors: Soo Jin Kim, Young Sang Kim, MinChae Kim, Young-Whan Park, Jung-Yong Kim, In Chull Kim
-
Patent number: 9944600Abstract: The present invention relates to novel piperidine derivatives, stereoisomers thereof or pharmaceutically acceptable salts thereof; methods for preparing the compound; and pharmaceutical compositions comprising the compound. The novel piperidine derivatives, according to the present invention, having an effect as GPR119 agonist can be used for treatment of metabolic disorders, including diabetes mellitus (especially type II) and related disorders.Type: GrantFiled: June 11, 2013Date of Patent: April 17, 2018Assignee: CHONG KUN DANG PHARMACEUTICAL CORP.Inventors: ChangSik Lee, TaegSu Jang, DaeKyu Choi, MooSung Ko, DoHoon Kim, SoYoung Kim, JaeKi Min, WooSik Kim, YoungTae Lim
-
Patent number: 9878986Abstract: Provided are urea derivatives of Formula I: with histone deacetylase (HDAC) inhibitory activity, optical isomers thereof, pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising the same. The provided urea derivatives of Formula I are selective histone deacetylase (HDAC) inhibitors and are effective for the treatment of histone deacetylase-mediated diseases such as malignant tumors, inflammatory diseases, rheumatoid arthritis, and neurodegeneration.Type: GrantFiled: April 29, 2014Date of Patent: January 30, 2018Assignee: Chong Kun Dang Pharmaceutical Corp.Inventors: Changsik Lee, Hyun-Mo Yang, Hojin Choi, Dohoon Kim, Soyoung Kim, Nina Ha, Hyojin Lim, Eunhee Ko, Seongae Yoon, Daekwon Bae
-
Patent number: 9839207Abstract: The present invention relates to a HSP27 mutation (S135F) mediated Charcot-Marie-Tooth disease (CMT) animal model. Particularly, the vector expressing mutant HSP27 protein wherein the 135th serine is substituted with phenylalanine has been injected in the mouse zygote and then the mouse harboring the expression vector was selected. The selected mouse was confirmed to display Charcot-Marie-Tooth disease phenotype, so that the animal model was expected to be efficiently used for the evaluation of the effect of Charcot-Marie-Tooth disease treating material candidates.Type: GrantFiled: October 1, 2015Date of Patent: December 12, 2017Assignees: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION, CHONG KUN DANG PHARMACEUTICAL CORPInventors: Yun Tae Kim, Byung-Ok Choi, Sung Chul Jung, Young Bin Hong, So-Youn Woo, Jin-Mo Park
-
Patent number: 9776987Abstract: The present invention relates to novel amide derivatives, stereoisomers thereof or pharmaceutically acceptable salts thereof; methods for preparing the compound; and pharmaceutical compositions comprising the compound. The novel amide derivatives, according to the present invention, having an effect as GPR119 agonist can be used for treatment of metabolic disorders, including diabetes mellitus (especially type II) and related disorders.Type: GrantFiled: November 25, 2014Date of Patent: October 3, 2017Assignee: CHONG KUN DANG PHARMACEUTICAL CORPInventors: Yuntae Kim, ChangSik Lee, DaeKyu Choi, MooSung Ko, Younghue Han, SoYoung Kim, JaeKi Min, DoHoon Kim
-
Patent number: 9650379Abstract: The present invention relates to novel azaindole derivatives, and more particularly, to novel azaindole derivatives having histone deacetylase (HDAC) inhibitory activity, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof or solvates thereof, the use thereof for the preparation of pharmaceutical compositions, pharmaceutical compositions containing the same, a method of treating disease using the pharmaceutical compositions, and methods for preparing the novel azaindole derivatives. The novel azaindole derivatives according to the present invention are selective histone deacetylase (HDAC) inhibitors, and may be used as agents for treating malignant tumor diseases, inflammatory diseases, rheumatoid arthritis, and neurodegenerative diseases.Type: GrantFiled: December 12, 2014Date of Patent: May 16, 2017Assignee: CHONG KUN DANG PHARMACEUTICAL CORP.Inventors: Changsik Lee, Hyun-Mo Yang, Changkon Lee, Miseon Bae, Soyoung Kim, Youngil Choi, Nina Ha, Jaekwang Lee, Jungtaek Oh, Hyeseung Song, Ilhyang Kim, Daekyu Choi, Jaeki Min, Hyojin Lim, Daekwon Bae
-
Publication number: 20170096405Abstract: The present invention relates to novel compounds having histone deacetylase 6 (HDAC6) inhibitory activity, isomers thereof, or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions comprising the same, a method of treating disease using the composition, and methods for preparing the novel compounds. The novel compounds according to the present invention have histone deacetylase 6 (HDAC6) inhibitory activity, and are effective for the prevention or treatment of HDAC6-associated diseases, including cancer, inflammatory diseases, autoimmune diseases, neurological diseases and neurodegenerative disorders.Type: ApplicationFiled: March 12, 2015Publication date: April 6, 2017Applicant: CHONG KUN DANG PHARMACEUTICAL CORP.Inventors: Hyeseung SONG, Changgon LEE, Dalyong KWAK, Jaeyoung LEE, Suyeal BAE, Yuntae KIM, Daekwon BAE, Nina HA, Miseon BAE, Jihyun KIM
-
Patent number: 9526787Abstract: Disclosed is a sustained release lipid pre-concentrate, comprising: a) a sorbitan unsaturated fatty acid ester having a polar head with at least two or more —OH (hydroxyl) groups; b) a phospholipid; and c) a liquid crystal hardener, free of an ionizable group, having a hydrophobic moiety of 15 to 40 carbon atoms with a triacyl group or a carbon ring structure. The lipid pre-concentrate exists as a liquid phase in the absence of aqueous fluid and forms into a liquid crystal in the presence of aqueous fluid. Also, a pharmaceutical composition further comprising a pharmacologically active ingredient plus the pre-concentrate is provided.Type: GrantFiled: August 28, 2012Date of Patent: December 27, 2016Assignee: Chong Kun Dang Pharmaceutical Corp.Inventors: Jin Young Ko, Ji Yeon Kim, So Hyun Park, Sung Won An, Min Hyo Ki
-
Publication number: 20160355475Abstract: The present invention provides a novel indole derivative compound, an isomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof. The compound according to the present invention can selectively inhibit histone deacetylase (HDAC), and thus can be used to effectively treat a disease associated with histone deacetylase (HDAC) activity.Type: ApplicationFiled: January 2, 2015Publication date: December 8, 2016Applicant: CHONG KUN DANG PHARMACEUTICAL CORP.Inventors: Changsik LEE, Hyun-Mo YANG, Dohoon KIM, Miseon BAE, Youngil CHOI, Nina HA
-
Patent number: 9493430Abstract: The present invention provides biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds, isomers thereof, or pharmaceutically acceptable salts. The compounds of the invention show a CETP inhibitory effect that increases HDL-cholesterol levels and reduces LDL-cholesterol levels. Pharmaceutical compositions comprising the compounds are useful for the prevention or treatment of dyslipidemia or dyslipidemia-related diseases.Type: GrantFiled: January 29, 2014Date of Patent: November 15, 2016Assignee: Chong Kun Dang Pharmaceutical Corp.Inventors: Jae Kwang Lee, Jung Taek Oh, Jae Won Lee, Seo Hee Lee, Il-Hyang Kim, Jae Young Lee, Su Yeal Bae, Se Ra Lee, Yun Tae Kim
-
Publication number: 20160289230Abstract: The present invention relates to novel azaindole derivatives, and more particularly, to novel azaindole derivatives having histone deacetylase (HDAC) inhibitory activity, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof or solvates thereof, the use thereof for the preparation of pharmaceutical compositions, pharmaceutical compositions containing the same, a method of treating disease using the pharmaceutical compositions, and methods for preparing the novel azaindole derivatives. The novel azaindole derivatives according to the present invention are selective histone deacetylase (HDAC) inhibitors, and may be used as agents for treating malignant tumor diseases, inflammatory diseases, rheumatoid arthritis, and neurodegenerative diseases.Type: ApplicationFiled: December 12, 2014Publication date: October 6, 2016Applicant: CHONG KUN DANG PHARMACEUTICAL CORP.Inventors: Changsik LEE, Hyun-Mo YANG, Changkon LEE, Miseon BAE, Soyoung KIM, Youngil CHOI, Nina HA, Jaekwang LEE, Jungtaek OH, Hyeseung SONG, Ilhyang KIM, Daekyu CHOI, Jaeki MIN, Hyojin LIM, Daekwon BAE
-
Patent number: 9447083Abstract: The present invention relates to novel N-acylhydrazone derivatives, and more particularly to novel N-acylhydrazone derivatives having selective T cell inhibitory activity and/or anti-lymphoid malignancy activity, stereoisomers thereof, pharmaceutically acceptable salts thereof, the use thereof for preparing pharmaceutical compositions, pharmaceutical compositions containing the same, treatment methods using the compositions, and methods for preparing the novel N-acylhydrazone derivatives.Type: GrantFiled: August 29, 2013Date of Patent: September 20, 2016Assignees: CHONG KUN DANG PHARMACEUTICAL CORP., INJE UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: HoJin Choi, JaeWon Lee, ChangGon Lee, NiNa Ha, Su Kil Seo, SunMi Lee, Song-Min Lee
-
Patent number: 9403912Abstract: The present invention relates to anti-ErbB2 antibody variants or antigen-binding fragments thereof, nucleic acid molecules encoding them, and their uses. The antibody variants of the present invention are capable of binding to ErbB2 with high affinity. Therefore, the antibody variants are ability to effectively prevent or treat various cancers with a low amount.Type: GrantFiled: April 26, 2013Date of Patent: August 2, 2016Assignee: CHONG KUN DANG PHARMACEUTICAL CORP.Inventors: Seung-Kee Moon, So-Ra Park, Ki-Young An
-
Patent number: 9371294Abstract: The present invention relates to cycloalkenyl aryl derivatives, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof, or solvates thereof; a method for preparing the derivatives; and pharmaceutical compositions containing the same. The compounds of the present invention show the effect of CETP activity inhibition. It means that the compounds can increase HDL-cholesterol and decrease LDL-cholesterol.Type: GrantFiled: April 12, 2012Date of Patent: June 21, 2016Assignee: CHONG KUN DANG PHARMACEUTICAL CORP.Inventors: SeoHee Lee, Jung Taek Oh, JaeKwang Lee, JaeWon Lee, Suyeal Bae, Nina Ha, Sera Lee
-
Publication number: 20160015010Abstract: The present invention relates to a HSP27 mutation (S135F) mediated Charcot-Marie-Tooth disease (CMT) animal model. Particularly, the vector expressing mutant HSP27 protein wherein the 135th serine is substituted with phenylalanine has been injected in the mouse zygote and then the mouse harboring the expression vector was selected. The selected mouse was confirmed to display Charcot-Marie-Tooth disease phenotype, so that the animal model was expected to be efficiently used for the evaluation of the effect of Charcot-Marie-Tooth disease treating material candidates.Type: ApplicationFiled: October 1, 2015Publication date: January 21, 2016Applicants: CHONG KUN DANG PHARMACEUTICAL CORP, SAMSUNG LIFE PUBLIC WELFARE FOUNDATIONInventors: Yun Tae Kim, Byung-Ok Choi, Sung Chul Jung, Young Bin Hong, So-Youn Woo, Jin-Mo Park
-
Publication number: 20160011177Abstract: The present invention relates to a method for the screening of a therapeutic agent for Charcot-Marie-Tooth disease (CMT) using induced pluripotent stem cells and motor neurons differentiated therefrom. Particularly, the present inventors prepared induced pluripotent stem cells from the human fibroblasts originated from CMT patient. When the motor neurons differentiated from the said induced pluripotent stem cells are used for the screening of a therapeutic agent for Charcot-Marie-Tooth disease, the pharmaceutical effect of the therapeutic agent candidates can be easily evaluated during the screening. In addition, by the method to prepare the induced pluripotent stem cells, autologous motor neurons which are usable for the screening of a patient-specific therapeutic agent and the patient-specific treatment can be prepared.Type: ApplicationFiled: October 1, 2015Publication date: January 14, 2016Applicants: CHONG KUN DANG PHARMACEUTICAL CORP, SAMSUNG LIFE PUBLIC WELFARE FOUNDATIONInventors: Yuntae Kim, Byung-Ok Choi, So-Youn Woo, Ji-Yon Kim, Sung Chul Jung, Young Bin Hong, Jin-Mo Park
-
Patent number: 9228218Abstract: The present invention relates to an expression vector for animal cells, comprising: (a) CSP-B (Cytotoxic Serine Protease-B) 5?-SAR (Scaffold or Matrix Attachment Region); (b) a promoter operable in animal cells; and (c) a polyadenylation sequence, and to a method for producing recombinant proteins using same. The vector of the present invention includes CSP-B 5?-SAR, and thus has the effect of overcoming the inhibition of gene expression according to the position of a foreign gene introduced into an animal cell, and significantly improving the expression rate of a target protein. The vector of the present invention effectively expresses recombinant proteins for drugs or antibodies in animal cells. The vector of the present invention and the method for producing recombinant proteins using same may be very usefully applied to the industrial mass production of drugs.Type: GrantFiled: May 21, 2012Date of Patent: January 5, 2016Assignee: CHONG KUN DANG PHARMACEUTICAL CORP.Inventors: Yeo-Wook Koh, Sang-Yong Lee, Su-Yon Kim, Seung-Kee Moon